SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Vennela Avula(Johns Hopkins University), Sarju Ganatra(Lahey Hospital and Medical Center), Teresa López‐Fernández(Hospital Universitario La Paz), Lauren A. Baldassarre(Yale University), Anita Deswal(The University of Texas MD Anderson Cancer Center), Ana Barac(Inova Fairfax Hospital), Marielle Scherrer‐Crosbie(University of Pennsylvania), Daniel J. Lenihan(Saint Francis Medical Center), Susan Dent(Government of the United States of America), Sumanth Khadke(Lahey Medical Center), Mikhail Kosiborod(AstraZeneca (Brazil)), Muthiah Vaduganathan(Brigham and Women's Hospital), Bonnie Ky(Virginia Commonwealth University), Tomas G. Neilan(Albert Einstein College of Medicine), Garima Sharma(Guru Nanak Dev University), Sourbha S. Dani(Lahey Medical Center), Jennifer Liu(Memorial Sloan Kettering Cancer Center), Anju Nohria(Brigham and Women's Hospital)
Cited by 100
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
The Global Health and Economic Burden of Hospitalizations for Heart Failure
|Journal of the American College of Cardiology|2014|2k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k